Circulation · 2009 · 122 citations · 29 references
MedicineBiochemistryCardiologyBiochemical PharmacologyClinical CardiologyPreventive CardiologyCardiovascular DiseaseFibrosisN-acetylcysteine TherapyCardiac Systolic FunctionCardiovascular BiologyCellular HypertrophyMuscle HypertrophyMyocardial MetabolismOxidative Stress In Cardiovascular DiseaseOxidative Stress InjurySystolic Dysfunction
BACKGROUND: Cardiac hypertrophy, the clinical hallmark of hypertrophic cardiomyopathy (HCM), is a major determinant of morbidity and mortality not only in HCM but also in a number of cardiovascular diseases. There is no effective therapy for HCM and generally for cardiac hypertrophy. Myocardial oxidative stress and thiol-sensitive signaling molecules are implicated in pathogenesis of hypertrophy and fibrosis. We posit that treatment with N-acetylcysteine, a precursor of glutathione, the largest intracellular thiol pool against oxidative stress, could reverse cardiac hypertrophy and fibrosis in HCM. METHODS AND RESULTS: We treated 2-year-old beta-myosin heavy-chain Q403 transgenic rabbits with established cardiac hypertrophy and preserved systolic function with N-acetylcysteine or a placebo for 12 months (n=10 per group). Transgenic rabbits in the placebo group had cardiac hypertrophy, fibrosis, systolic dysfunction, increased oxidized to total glutathione ratio, higher levels of activated thiol-sensitive active protein kinase G, dephosphorylated nuclear factor of activated T cells (NFATc1) and phospho-p38, and reduced levels of glutathiolated cardiac alpha-actin. Treatment with N-acetylcysteine restored oxidized to total glutathione ratio, normalized levels of glutathiolated cardiac alpha-actin, reversed cardiac and myocyte hypertrophy and interstitial fibrosis, reduced the propensity for ventricular arrhythmias, prevented cardiac dysfunction, restored myocardial levels of active protein kinase G, and dephosphorylated NFATc1 and phospho-p38. CONCLUSIONS: Treatment with N-acetylcysteine, a safe prodrug against oxidation, reversed established cardiac phenotype in a transgenic rabbit model of human HCM. Because there is no effective pharmacological therapy for HCM and given that hypertrophy, fibrosis, and cardiac dysfunction are common and major predictors of clinical outcomes, the findings could have implications in various cardiovascular disorders.
29
Actin Dynamics Control SRF Activity by Regulation of Its Coactivator MAL
Francesc Miralles, Guido Posern, Alexia-Ileana Zaromytidou et al. · Cell · 2003 · 1.3K citations · Full text
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Maurits Demedts, Roland Buhl, Ulrich Costabel et al. · New England Journal of Medicine · 2005 · 981 citations · Full text